RATIONALE-304 trial: what clinicians have said so far
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
- NCT03663205 ↗
- Completed
- BeiGene
- Focused size, estimated: 1–150 verified statements once built
Discussed at: European Lung Cancer Congress 2026
We haven't built an HCP commentary report on RATIONALE-304 (tislelizumab in first-line advanced non-squamous non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RATIONALE-304 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 6 posts on X, typically up to 26 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) (Anti-PD1 Antibody) Combined With Platinum-Pemetrexed Versus Platinum-Pemetrexed Alone as First-line Treatment for Patients With Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Tislelizumab; Cisplatin; Carboplatin; Pemetrexed
- Arms
- Tislelizumab + Platinum + Pemetrexed · Experimental
- Platinum + Pemetrexed · Active comparator
- Enrollment
- 334
- Primary outcomes
- Progression Free Survival (PFS) Assessed by Independent Review Committee (IRC) Assessment
- Sponsor
- BeiGene
- Start
- Jul 23, 2018
- Primary completion
- Jan 23, 2020
- Results posted
- Yes
- Registry record
- NCT03663205 · updated Feb 4, 2025
Publications
linked from the registry- Lu S, Wang J, Yu Y, Yu X, Hu Y, Ai X, Ma Z, Li X, Zhuang W, Liu Y, Li W, Cui J, Wang D, Liao W, Zhou J, Wang Z, Sun Y, Qiu X, Gao J, Bao Y, Liang L, Wang M. Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial. J Thorac Oncol. 2021 Sep;16(9):1512-1522. doi: 10.1016/j.jtho.2021.05.005. Epub 2021 May 23. PubMed 34033975
- Lu S, Wang J, Yu Y, Yu X, Hu Y, Wangjun L, Li X, Liu Y, Li W, Qu X, Bao Y, Wang M. First-Line Tislelizumab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: PD-L1 >/= 50% Subgroup Analysis from the RATIONALE-304 Trial. Oncol Ther. 2025 Dec;13(4):1087-1104. doi: 10.1007/s40487-025-00378-8. Epub 2025 Sep 14. PubMed 40946254
- Lu S, Yu Y, Barnes G, Qiu X, Bao Y, Tang B. Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non-Small Cell Lung Cancer. Cancer J. 2022 Mar-Apr 01;28(2):96-104. doi: 10.1097/PPO.0000000000000583. PubMed 35333492